GeneLeuk Biopharmaceutical

GeneLeuk Biopharmaceutical, officially Shandong GeneLeuk Biopharmaceutical Co., Ltd., is a Chinese biotechnology company founded in 1999 as a Sino-US joint venture. Headquartered in Jinan, the company specializes in the research, development, and manufacturing of recombinant protein-based pharmaceuticals, most notably GeneLeukim (rhG-CSF) for the treatment of chemotherapy-induced neutropenia. Following its acquisition by CSPC Pharmaceutical Group, it was integrated into CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Today, the company serves as a key biologics arm for CSPC, producing blockbuster products like Jinyouli (PEG-Filgrastim) and advancing a pipeline of innovative therapies in oncology and metabolic diseases, including long-acting GLP-1 fusion proteins.